PTEN polymorphisms contribute to clinical outcomes of advanced lung adenocarcinoma patients treated with platinum-based chemotherapy

Tumor Biology

Volumn 37, Issue 6, 2016, Pages 7785-7796

  Yang, Yang ^a   Xu, Wen ^b   Liu, Di ^b   Ding, Xi ^b   Su, Bo ^b   Sun, Yifeng ^a   Gao, Wen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chemotherapy; Lung adenocarcinoma; Platinum; PTEN; Single nucleotide polymorphisms

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; ANTINEOPLASTIC AGENT; PTEN PROTEIN, HUMAN; TUMOR PROTEIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; ADVANCED CANCER; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE CONTROL; DNA DETERMINATION; DRUG EFFICACY; FEMALE; GENE FREQUENCY; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PTEN GENE; SINGLE NUCLEOTIDE POLYMORPHISM; ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; GENOTYPE; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PTEN PHOSPHOHYDROLASE;

EID: 84951753067     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4651-0     Document Type: Article

References (24)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. Pilkington G, Boland A, Brown T, Oyee J, Bagust A, Dickson R. A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. Thorax. 2015;70:359–67.
3. Shi Y, Sun Y. Medical management of lung cancer: experience in China. Thorac Cancer. 2015;6:10–6.
4. Lee Y, Yoon KA, Joo J, Lee D, Bae K, Han JY, et al. Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study. Carcinogenesis. 2013;34:307–13.
5. Giovannetti E, Toffalorio F, De Pas T, Peters GJ. Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape? Pharmacogenomics. 2012;13:1073–86.
6. Loktionov A. Common gene polymorphisms, cancer progression and prognosis. Cancer Lett. 2004;208:1–33.
7. Yin Y, Shen WH. PTEN: a new guardian of the genome. Oncogene. 2008;27:5443–53.
8. Cao Q, Ju X, Li P, Meng X, Shao P, Cai H, et al. A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk. PLoS One. 2012;7:e50302.
9. Xu X, Chen G, Wu L, Liu L. Association of genetic polymorphisms in PTEN and additional gene-gene interaction with risk of esophageal squamous cell carcinoma in Chinese Han population. Dis Esophagus. 2015. doi:10.1111/dote.12428.
10. Wang X, Lin Y, Lan F, Yu Y, Ouyang X, Wang X, et al. A GG allele of 3′-side AKT1 SNP is associated with decreased AKT1 activation and better prognosis of gastric cancer. J Cancer Res Clin Oncol. 2014;140:1399–411.
11. Zhang X, Chen X, Zhai Y, Cui Y, Cao P, Zhang H, et al. Combined effects of genetic variants of the PTEN, AKT1, MDM2 and p53 genes on the risk of nasopharyngeal carcinoma. PLoS One. 2014;9:e92135.
12. Jing F, Mao Y, Zhang Z, Li Y, Cai S, Li Q, et al. The association of phosphatase and tensin homolog deleted on chromosome 10 polymorphisms and lifestyle habits with colorectal cancer risk in a Chinese population. Tumor Biol. 2014;35:9233–40.
13. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.
14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
15. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–65.
16. Stephens M, Smith MJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978–89.
17. Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N, et al. PTEN: multiple functions in human malignant tumors. Fron Oncol. 2015;5:24.
18. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–7.
19. Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res. 2002;8:1178–84.
20. Lee S, Choi EJ, Jin C, Kim DH. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol. 2005;97:26–34.
21. Forgacs E, Biesterveld EJ, Sekido Y, Fong K, Muneer S, Wistuba II, et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene. 1998;17:1557–65.
22. Marsit CJ, Zheng S, Aldape K, Hinds PW, Nelson HH, Wiencke JK, et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol. 2005;36:768–76.
23. Mignone F, Gissi C, Liuni S, Pesole G. Untranslated regions of mRNAs. Genome Biol. 2002;3:REVIEWS0004.
24. Conne B, Stutz A, Vassalli JD. The 3 untranslated region of messenger RNA: a molecular ‘hotspot’ for pathology? Nat Med. 2000;6:637–41.